These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7968752)

  • 1. Quality of life six months after myocardial infarction treated with thrombolytic therapy. AUS-TASK Group. Australian arm of International tPA/SK Mortality Trial.
    Glasziou PP; Bromwich S; Simes RJ
    Med J Aust; 1994 Nov; 161(9):532-6. PubMed ID: 7968752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
    Lancet; 1990 Jul; 336(8707):65-71. PubMed ID: 1975321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
    Kalish SC; Gurwitz JH; Krumholz HM; Avorn J
    J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thrombolysis in acute myocardial infarction. Streptokinase or r-TPA?].
    Silva LA; Ribeiro E; Carneiro RC; Kaissar S; Reis Filho A; Torossian SP; Tavares JR; Buffolo E; Amino JG; Duprat Filho R
    Arq Bras Cardiol; 1990 Jul; 55(1):13-7. PubMed ID: 2127353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
    GUSTO investigators
    N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective.
    Heyland DK; Gafni A; Levine MA
    J Clin Epidemiol; 2000 Sep; 53(9):888-94. PubMed ID: 11004415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group.
    Lancet; 1990 Jul; 336(8707):71-5. PubMed ID: 1975322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: A decision analysis.
    Hiatt MD
    Cardiology; 1999; 91(4):243-9. PubMed ID: 10545680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.
    Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM
    Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteplase (r-TPA) vs streptokinase.
    Hunt D
    Aust N Z J Med; 1998 Aug; 28(4):514-7. PubMed ID: 9777131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction.
    Kellett J; Clarke J
    Med Decis Making; 1995; 15(4):297-310. PubMed ID: 8544674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous thrombolytic therapy in myocardial infarction: an analytical review.
    Shammas NW; Zeitler R; Fitzpatrick P
    Clin Cardiol; 1993 Apr; 16(4):283-92. PubMed ID: 8458108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator.
    Agostoni A; Gardinali M; Frangi D; Cafaro C; Conciato L; Sponzilli C; Salvioni A; Cugno M; Cicardi M
    Circulation; 1994 Dec; 90(6):2666-70. PubMed ID: 7994806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
    Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
    J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
    Barbash GI; White HD; Modan M; Van de Werf F
    J Am Coll Cardiol; 1993 Sep; 22(3):707-13. PubMed ID: 8354802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient preferences for thrombolytic therapy in acute myocardial infarction.
    Stanek EJ; Cheng JW; Peeples PJ; Simko RJ; Spinler SA
    Med Decis Making; 1997; 17(4):464-71. PubMed ID: 9343805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial.
    White HD; Barbash GI; Califf RM; Simes RJ; Granger CB; Weaver WD; Kleiman NS; Aylward PE; Gore JM; Vahanian A; Lee KL; Ross AM; Topol EJ
    Circulation; 1996 Oct; 94(8):1826-33. PubMed ID: 8873656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.